UpdatesGeneral Updates
Mangalam Drugs' FY25 revenue fell to ₹318.73 Cr, yet PAT improved to ₹6.72 Cr from a loss.
Mangalam Drugs And Organics LimitedMANGALAM · Filed with the exchange
The company expanded its anti-malaria API portfolio with Pyronaridine and initiated in-house critical API manufacturing.
A merger scheme was approved by the Board, and subsidiary property revaluation added ₹7.08 Cr surplus.
No dividend proposed.
No comments yet. Be the first.